- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose…
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous…
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first…
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first…
NEW YORK--(BUSINESS WIRE)--In response to the recent executive budget decision by Governor Kathy Hochul, which includes a substantial $125 million…
PHILADELPHIA, PA / ACCESSWIRE / February 23, 2024 / CGFNS International announced today it has established a Global Health Workforce…
Living our Purpose: This Patient Services colleague left an impression on a Quest patient of 30 yearsNORTHAMPTON, MA / ACCESSWIRE…
SOMERSET, NJ / ACCESSWIRE / February 23, 2024 / Americord, a leading private stem cell bank, announced the release of…
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of…
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided…